Telix Pharmaceuticals Posts 22% Revenue Growth in H1 2026 as ProstACT Global and Regeneron Collaboration Advance

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, reported half-year 2026 results on August 20, 2026 showing group revenue of $477 million, up 22% year over year and tracking toward the upper end of full-year guidance of $950 million to $970 million. Adjusted EBITDA reached $52 million, up 146% year over year, helped by a $40 million non-refundable upfront payment from a new Regeneron collaboration. Telix generated $23 million in positive operating cash flow and ended the period with a $252 million cash balance, while advancing ProstACT Global, its lead late-stage prostate cancer therapy program, into its next enrollment phase.

Precision Medicine Segment Delivers Volume Growth and Regulatory Progress

Telix’s commercial engine, the Precision Medicine segment, grew revenue 27% year over year on continued strength from its two-product imaging strategy: Illuccix and Gozellix both delivered sales volume growth and market share gains, pushing segment gross margin to 65% and segment adjusted EBITDA up 26% to $132 million. Regulatory momentum extended beyond the existing commercial base. China’s National Medical Products Administration accepted Telix’s new drug application for Illuccix for review, and the company completed enrollment in Illuccix’s Japan Phase 3 registrational study. On the neuro-oncology imaging side, Pixclara received an FDA PDUFA goal date of September 11, 2026, and its European counterpart Pixlumi had its Marketing Authorization Application validated and accepted for review. Telix also secured an extension on its BLA resubmission deadline for Zircaix, its kidney cancer imaging candidate, following a corrected Complete Response Letter, and continues working with the FDA to address the outstanding items.

ProstACT Global Clears a Key FDA Checkpoint as the Therapeutics Pipeline Advances on Multiple Fronts

The therapeutics side of the business, where Telix invested $68 million of its $124 million total H1 R&D spend, delivered the period’s most consequential clinical news. ProstACT Global’s Part 1 lead-in, evaluating TLX591-Tx in metastatic castration-resistant prostate cancer, met its safety and dosimetry objectives with no new safety signals. The FDA confirmed that data was sufficient to progress to Part 2 and aligned with Telix on the Part 2 protocol, with enrollment now underway across Australia, Canada, New Zealand, Singapore, South Korea, Türkiye, and the United Kingdom. Alongside that flagship program, Telix dosed its first LUTEON trial patient for TLX250-Tx in advanced kidney cancer, enrolled the first patient cohort in the IPAX BrIGHT pivotal trial for TLX101-Tx in recurrent glioblastoma, and completed enrollment in two additional mid-stage studies (OPTIMAL-PSMA and IPAX-2). Five distinct late-stage or pivotal programs advancing in parallel gives Telix a therapeutics pipeline with multiple independent shots on goal rather than a single binary bet.

Regeneron Partnership and Balance Sheet Moves Fund the Next Phase

Telix backed its expanding pipeline with two significant corporate actions. The company entered a strategic collaboration with Regeneron in April 2026 to jointly develop and commercialize next-generation radiopharmaceutical therapies, an agreement that has already delivered a $40 million non-refundable upfront payment reflected in H1 results. Separately, Telix refinanced its convertible bond structure, issuing $600 million of new convertible bonds due 2031, and on the day of these results also entered an at-the-market equity distribution agreement with Morgan Stanley and William Blair to provide additional capital-raising flexibility on Nasdaq. Telix Manufacturing Solutions, the company’s production and supply chain segment spanning facilities in the U.S., Belgium, Australia, and Japan, posted $146 million in total segment revenue, though its adjusted EBITDA loss widened to $23 million as the company invests ahead of anticipated therapeutics infrastructure needs—a deliberate trade-off management is making to support the pipeline’s eventual commercial scale.

Strategic Investment Summary

• H1 2026 Financials: Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) reported $477 million in group revenue, up 22% year over year, and adjusted EBITDA of $52 million, up 146%, with $252 million in cash and positive operating cash flow of $23 million as of June 30, 2026.
• Precision Medicine Growth: The Precision Medicine segment grew revenue 27% year over year with 65% gross margin, driven by Illuccix and Gozellix volume and share gains, alongside a Chinese NMPA filing acceptance and Japan Phase 3 enrollment completion for Illuccix.
• ProstACT Global Milestone: ProstACT Global Part 1 met its safety and dosimetry objectives with no new safety signals; the FDA confirmed sufficiency to progress and aligned on the Part 2 protocol, which is now enrolling across seven countries.
• Regeneron Collaboration: A strategic radiopharmaceutical collaboration entered with Regeneron in April 2026 delivered a $40 million non-refundable upfront payment reflected in H1 results, with further milestone and royalty potential ahead.
• Pipeline Breadth: Beyond ProstACT Global, Telix dosed first patients in the LUTEON kidney cancer trial and the IPAX BrIGHT glioblastoma trial, and completed enrollment in two additional mid-stage studies, giving the therapeutics pipeline five active late-stage or pivotal programs.
• Capital Structure: Telix refinanced its convertible bonds with a $600 million issuance due 2031 and entered an at-the-market equity facility with Morgan Stanley and William Blair on August 20, 2026, adding capital-raising flexibility as R&D investment scales.

Find out more about the latest clinical updates and financial reports at the Telix Pharmaceuticals investor portal.